# Phase 1 osteosarcoma trials recruiting: 22 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials in phase 1 for osteosarcoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 osteosarcoma trials: 22 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/osteosarcoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 22
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 27, 2026 | NCT07897968 | GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors | Universität Münster | Phase 1 | Not yet recruiting | Neuroblastoma (NBL), Ewing Sarcoma, Osteosarcoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897968) |
| June 15, 2026 | NCT07648069 | Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma | Sun Yat-sen University | Phase 1 | Recruiting | Soft Tissue Sarcoma (STS), Osteosarcoma | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648069) |
| November 12, 2025 | NCT07227571 | Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma... | Fred Hutchinson Cancer Center | Phase 1 | Recruiting | Advanced Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227571) |
| October 8, 2025 | NCT07211737 | NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma | Baylor College of Medicine | Phase 1 | Recruiting | Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07211737) |
| August 27, 2025 | NCT07144254 | Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma | Emory University | Phase 1 | Recruiting | Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07144254) |
| November 21, 2024 | NCT06699576 | ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. | Hansoh BioMedical R&D Company | Phase 1 | Not yet recruiting | Osteosarcoma, Soft Tissue Sarcoma (STS) | 448 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06699576) |
| August 1, 2024 | NCT06531486 | A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Recruiting | Solid Tumor, Ovarian Cancer, Breast Cancer, Endometrial Cancer, Osteosarcoma | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06531486) |
| July 15, 2024 | NCT06500819 | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors | Stanford University | Phase 1 | Recruiting | Neuroblastoma, Sarcoma, Osteosarcoma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06500819) |
| July 9, 2024 | NCT06492954 | Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma | Emory University | Phase 1 | Recruiting | Osteosarcoma, Pulmonary Recurrence of Osteosarcoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06492954) |
| January 31, 2024 | NCT06235125 | Safety and Feasibility of Intraoperative Visualization With Cytalux in Children | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 1 | Recruiting | Osteosarcoma, Pulmonary Metastasis, Fluorescence, Metastatic Sarcoma, Pediatrics | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06235125) |
| December 5, 2023 | NCT06156410 | Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas | Children's Hospital of Philadelphia | Phase 1 | Recruiting | Ewing Sarcoma, Osteosarcoma, Sarcomas | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06156410) |
| August 8, 2022 | NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | Valo Therapeutics Oy | Phase 1 | Recruiting | Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Synovial Sarcoma, Myxoid Liposarcoma... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05492682) |
| June 1, 2022 | NCT05400603 | Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed... | Emory University | Phase 1 | Recruiting | Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05400603) |
| February 7, 2022 | NCT05227326 | AOH1996 for the Treatment of Refractory Solid Tumors | City of Hope Medical Center | Phase 1 | Recruiting | Refractory Malignant Solid Neoplasm, Osteosarcoma, Leiomyosarcomas, Synovial Sarcomas, Ovarian Cancer, Non-Small Cell... | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05227326) |
| January 27, 2022 | NCT05210374 | Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas | Case Comprehensive Cancer Center | Phase 1 | Recruiting | Relapsed Sarcomas | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05210374) |
| August 6, 2021 | NCT04995003 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | Baylor College of Medicine | Phase 1 | Recruiting | Sarcoma, HER-2 Protein Overexpression, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma, Synovial Sarcoma, Soft Tissue... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04995003) |
| May 21, 2021 | NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | St. Jude Children's Research Hospital | Phase 1 | Recruiting | Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Ewing Sarcoma, Wilms Tumor, Adrenocortical... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04897321) |
| April 3, 2019 | NCT03900793 | Losartan + Sunitinib in Treatment of Osteosarcoma | University of Colorado, Denver | Phase 1 | Recruiting | Osteosarcoma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03900793) |
| October 26, 2018 | NCT03721068 | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | UNC Lineberger Comprehensive Cancer Center | Phase 1 | Recruiting | Neuroblastoma, Osteosarcoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03721068) |
| March 28, 2017 | NCT03093909 | Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms... | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03093909) |
| July 24, 2015 | NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | University of Wisconsin, Madison | Phase 1 | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome... | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02508038) |
| December 17, 2013 | NCT02013336 | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or... | South Plains Oncology Consortium | Phase 1 | Recruiting | Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02013336) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Emory University | 3 |
| Baylor College of Medicine | 2 |
| M.D. Anderson Cancer Center | 1 |
| Children's Hospital of Philadelphia | 1 |
| Fred Hutchinson Cancer Center | 1 |
| [Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.](https://specstream.ai/data/clinical-trials/company/shanghai-fosun-pharmaceutical-industrial-development-co-ltd) | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| Sun Yat-sen University | 1 |
| Case Comprehensive Cancer Center | 1 |
| City of Hope Medical Center | 1 |
| University of Colorado, Denver | 1 |
| [Hansoh BioMedical R&D Company](https://specstream.ai/data/clinical-trials/company/hansoh-biomedical-r-and-d-company) | 1 |
| University of Wisconsin, Madison | 1 |
| Stanford University | 1 |
| Universität Münster | 1 |
| Valo Therapeutics Oy | 1 |
| Ann & Robert H Lurie Children's Hospital of Chicago | 1 |
| St. Jude Children's Research Hospital | 1 |
| South Plains Oncology Consortium | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 17 |
| China | 2 |
| Germany | 2 |
| Italy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Landscape architecture firms in the United States](https://specstream.ai/data/businesses/landscape-architecture-firms/united-states)
- [Senegalese restaurants in the United States](https://specstream.ai/data/businesses/senegalese-restaurants/united-states)
- [B2B quarry companies in the United States](https://specstream.ai/data/businesses/b2b-quarry-companies/united-states)
- [Fast food restaurants in the United States](https://specstream.ai/data/businesses/fast-food-restaurants/united-states)
- [Nigerian restaurants in the United States](https://specstream.ai/data/businesses/nigerian-restaurants/united-states)
- [Tractor dealers in the United States](https://specstream.ai/data/businesses/tractor-dealers/united-states)
